VPS51 inhibitors are a class of chemical compounds specifically designed to target and inhibit the VPS51 protein, which is a component of the Golgi-associated retrograde protein (GARP) complex. The VPS51 protein plays a crucial role in the intracellular trafficking system, particularly in the retrograde transport of vesicles from endosomes back to the trans-Golgi network. This transport system is essential for maintaining cellular homeostasis and ensuring that proteins and lipids are correctly sorted and delivered to their intended destinations within the cell. VPS51, as part of the GARP complex, interacts with other proteins such as VPS52, VPS53, and VPS54 to facilitate the tethering of vesicles to the Golgi, which is a key step in the retrograde transport pathway. Inhibitors of VPS51 are designed to disrupt this interaction, thereby impairing the function of the GARP complex and the overall retrograde transport process.
The development of VPS51 inhibitors involves a detailed understanding of the protein's structure and its interactions within the GARP complex. Researchers use techniques like X-ray crystallography, cryo-electron microscopy, and molecular docking to elucidate the binding sites and interaction domains of VPS51. This structural information is crucial for designing small molecules that can effectively bind to VPS51 and inhibit its function. High-throughput screening of chemical libraries is often employed to identify lead compounds with inhibitory activity against VPS51. These lead compounds are then further optimized through structure-activity relationship (SAR) studies, where chemical modifications are made to improve binding affinity, selectivity, and stability. Factors such as solubility, lipophilicity, and metabolic stability are also taken into consideration to ensure that the inhibitors are effective under physiological conditions. By inhibiting VPS51, researchers can explore the broader implications of disrupting the GARP complex and retrograde transport, offering insights into the fundamental processes of intracellular trafficking and protein sorting.
Items 1 to 10 of 20 total
展示:
产品名称 | CAS # | 产品编号 | 数量 | 价格 | 应用 | 排名 |
---|---|---|---|---|---|---|
Amiloride | 2609-46-3 | sc-337527 | 1 g | $290.00 | 7 | |
钠通道抑制剂,可间接调节细胞离子平衡,影响 Olr1513。 | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $48.00 $122.00 $432.00 $812.00 | 4 | |
Wiskostatin 能特异性抑制对肌动蛋白聚合至关重要的 N-WASP-Arp2/3 复合物。这种抑制会阻碍囊泡运动所需的肌动蛋白结构的正常形成,从而破坏囊泡的贩运过程,而已知 VPS51 也参与了囊泡的贩运过程。 | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $122.00 $235.00 $520.00 $979.00 $1500.00 | 2 | |
β-肾上腺素能拮抗剂可能会间接影响细胞信号,从而影响 Olr1513。 | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $87.00 | 44 | |
Dynasore是一种强效的dynamin抑制剂,dynamin是一种参与囊泡分裂的GTP酶。通过抑制动力蛋白,内吞囊泡的形成受到阻碍,这可能会导致VPS51的功能抑制,使其无法在囊泡运输中发挥作用。 | ||||||
12β-Hydroxydigitoxin | 20830-75-5 | sc-213604 sc-213604A | 1 g 5 g | $140.00 $680.00 | ||
强心苷可能会间接影响细胞离子动力学,从而影响 Olr1513。 | ||||||
Eplerenone | 107724-20-9 | sc-203943 sc-203943A | 10 mg 50 mg | $108.00 $612.00 | 4 | |
矿质皮质激素受体拮抗剂,可能间接调节激素途径,影响 Olr1513。 | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $134.00 $502.00 | 7 | |
ML141 是一种 Cdc42 GTPase 抑制剂,通过抑制 Cdc42,可导致细胞骨架组织和囊泡贩运受到干扰。由于 VPS51 是囊泡转运途径的一部分,它的功能会因为囊泡形成和转运的中断而受到抑制。 | ||||||
2-(Benzoylcarbamothioylamino)-5,5-dimethyl-4,7-dihydrothieno[2,3-c]pyran-3-carboxylic Acid | 314042-01-8 | sc-503400 | 10 mg | $300.00 | ||
CID 1067700可抑制ARF-GEF蛋白的Sec7结构域,该结构域对于高尔基体囊泡的形成至关重要。由于VPS51参与高尔基体相关囊泡运输,因此囊泡形成受阻会导致其功能被抑制。 | ||||||
Felodipine | 72509-76-3 | sc-201483 sc-201483A | 10 mg 50 mg | $89.00 $218.00 | 1 | |
钙通道阻滞剂,可间接改变钙信号传导,影响 Olr1513。 | ||||||
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | $28.00 $37.00 | 18 | |
非甾体抗炎药可能会间接调节炎症途径,影响 Olr1513。 |